Cookie Consent

Zeulab use its own and third-party cookies while browsing the website, which allows access to the website's functionalities, for analytical purposes and to extract traffic statistics to improve the user experience. You can accept all cookies, as well as configure your preferences. For more information, you can consult our Privacy and Cookies Policy

Setting preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies in each consent category below.

Out of these, cookies that are categorized as “Necessary” are stored on your browser as they are essential to enable basic functionalities of the website.... 

Always active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display

+ (34) 976 731 533

Zeulab

Pedro Razquin

Pedro Razquin is Owner and CEO at ZEULAB, he is also President of the biotechnology cluster of Aragon. Developing solutions for Food Security.

DATA REVIEW: How to detect the 128 authorized medicines for mastitis?

15 Apr 2020

Posted at 10:45h in Antibiotic Residues Dairy by

Spanish Agency for Medicines and Health Products (AEMPS) authorizes a total of 128 drugs for treatment of mastitis in dairy cattle in Spain.

A study carried out by our company in November 2019 with information available from CIMAVet shows that 34.4% of them are beta-lactams, 28.9% quinolones, 13,3% macrolides and 10.2% tetracyclines. Aminoglycosides (7%), sulfonamides (2.3%) and other antibiotics of different chemical structure (3.9%) complete the whole list.

 

mastitis

A scheme for antibiotic residues control in milk should be designed to detect as many substances as possible at the legal level and with the appropriate frequency and affordable cost.

The most effective solution to detect 90% of these drugs at the legal level (EU-MRL) and 8% more at twice the regulatory limits is to combine two complementary tests: Eclipse and QuinoScan. Both tests are very easy and can be run by any user without previous training. Results obtained by both tests are loaded in an online platform. So, they are always available on the computer or any smart device.

tabla mastitisTable. Antibiotics detected with the combined tests of Eclipse&QuinoScan. Column 1 shows the percentage of authorised antibiotics for each group. Column 2 the total number of medicines. Column 3 the level of detection, as equal to MRL, less sensitive than MRL or twice the MRL. In brackets the number of antibiotics detected at that level.

Print page
0 Likes